Dhingra Kapil, Director at Five Prime Therapeutics, holds 0.00 shares in Five Prime Therapeutics (Ticker: FPRX), holds 0.00 shares in Replimune Group (Ticker: REPL), holds ― shares in Black Diamond Therapeutics (Ticker: BDTX). Most recently, Dhingra Kapil ― shares of Five Prime Therapeutics on ― for an estimated value of ―.
Dhingra Kapil latest transaction was an Uninformative Buy of ―.
What was Dhingra Kapil's most profitable transaction?
Dhingra Kapil’s most profitable transaction was an Informative Sell of REPL stock on December 11, 2025. The return on the trade was -3.10%.
What is Dhingra Kapil's role in Five Prime Therapeutics?
Dhingra Kapil's role in Five Prime Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.